Bao Le

Consejero General en SENSEI BIOTHERAPEUTICS, INC. .

Health Technology

Perfil

Bao Le is currently the Vice President of Regulatory Affairs at Sensei Biotherapeutics, Inc. She started this job in 2021.
Previously, she worked as the Vice President and Head of Global Regulatory Affairs at enGene, Inc.

Cargos activos de Bao Le

Empresas	Cargo	Inicio
SENSEI BIOTHERAPEUTICS, INC.	Consejero General	01/06/2021

Todos los cargos activos de Bao Le

Antiguos cargos conocidos de Bao Le.

Empresas	Cargo	Fin
enGene, Inc. enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.	Consejero General	-

Ver el detalle de la experiencia de Bao Le.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Bao Le.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
SENSEI BIOTHERAPEUTICS, INC.	Health Technology

Empresas privadas	1
enGene, Inc. enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.	Health Technology